Associated Press | CNN News
Medivation Inc. (NASDAQ:MDVN) Monday said its selective androgen receptor modulator, MDV3100, showed substantial reductions in serum levels of prostate specific antigen in six patients in a phase 1-2 trial.
The San Francisco-based biopharmaceutical company said its MDV3100 is used to treat hormone refractory prostate cancer.
The company said it expects to complete the study and report the results in 2008.
The stock closed Friday at $21.09.
Comments: Leave a comment
*Bold labels are required.
Bold labels are required.
Feb 09, 2012 | Finz & Finz, P.C.
Plaintiff's infant daughter allegedly sustained personal injuries as a result of a ear piercings by the defendants. Plaintiff claims that because of defendants' negligent performance of the piercing, her daughter "sustained scar tissue on her left ear, an improperly placed...
Feb 02, 2012 | Finz & Finz, P.C.
In car accidents it is often the case that the person driving the car is not the owner of the vehicle. Plaintiff's subrogors were injured when the son of the defendant negligently operated his mother's motor vehicle which resulted in...
Finz & Finz, P.C.
410 East Jericho Turnpike
Mineola
NY
11501
Telephone: (516) 433-3000
Telephone: (855) TOP-FIRM
Fax: (516) 433-3001
Mineola Law Office
Finz & Finz, P.C.
44 Wall Street
New York
NY
10005
Telephone: (212) 513-1000
Telephone: (855) TOP-FIRM
Fax: (212) 513-7707
New York Law Office
© 2012 by Finz & Finz, P.C.. All rights reserved. Disclaimer | Site Map
Privacy Policy | FirmSite® by FindLaw, a Thomson Reuters business.
No Comments
Leave a comment